Key Takeaways
- Revenue held up, but the mix was flattered: 15% YoY revenue growth to INR148 crores was driven by a one-time consumer segment spike, while the core industrial business stayed subdued on demand weakness and customer year-end closures.
- Pakhajan ramp-up is running two quarters late: Utilization hit only ~30% in December, with sales slipping into January; the plant is now expected to cross 50% utilization only from March 2025.
- FY26 guidance set at INR950–1,000 crores revenue, 17–19% EBITDA margin: Management laid out a clear two-year path, with FY27 revenue of INR1,250–1,300 crores assuming both plants run full from day one.
- INR125 crores fundraise closed to relieve the balance sheet: INR50 crores goes to debt repayment, INR75 crores to working capital and future expansion; the move was framed as pre-emptive, to avoid stressing finances during the ramp-up delay.
- What to watch next quarter: Whether the promised 30–35% Q4 volume growth materializes, whether inventory normalizes by March, and any early signals from the new US subsidiary that begins selling in March.
Pakhajan Ramp-Up: The Core Execution Story
- Two-quarter delay confirmed: Full approvals were not in place for some customers, RFQs for long-term contracts were not ready, and December year-end closures meant customers refused material; production and sales are now lagging about two quarters behind the September expectation.
- Utilization trajectory: December utilization was close to 30%, but sales did not materialize; many sales happened in January instead. Q4 blended utilization is targeted at 35–40%, with an exit run rate of 85–90% by the last quarter of FY26.
- Full monetization is a 3–4 year story: INR250 crores was spent on peripheral infrastructure; a second phase of expansion is needed to utilize those assets fully, and that will take two more years from now.
- New product capex trigger: Will happen in FY26, but only once Pakhajan utilization surpasses 70%; management declined to comment on whether brownfield execution would be faster, calling it premature.
Parag Jhaveri: "Pakhajan is not fully monetized. It will take at least to monetize the full assets of Pakhajan, we will need 3 years minimum 3 to 4 years purely because we have spent about INR250 crores on peripheral infrastructure creation."
Revenue Mix & Demand Dynamics
- Consumer spike was one-time: Consumer chemical business grew very strongly in Q3 and 9M FY25, but management explicitly stated it will not grow this way going forward; industrial segment sales were subdued due to demand weakness and December year-end for MNC customers, making consumer share appear higher than reality.
- Industrial contribution fell but margins held: Industrial chemicals contribution dropped to 79% from 87% YoY, yet gross margins expanded because certain high-margin industrial products sold in low quantity were sold in larger volume, improving the overall mix.
- Customer qualification gap now closed: Some bids were previously lost because the company was not fully qualified; management confirmed qualification is now achieved with those customers.
- Major RFQ cycle starts mid-2025: Major customer RFQs for new purchase are expected to come in July and August.
- Price improvement emerging: Some price improvements started from mid-January; prices have started rising across the board.
Parag Jhaveri: "No, it will be onetime. We don't expect that to grow this. This is purely that our sales into the industrial segment were a little subdued due to the demand and also the year-end for a lot of customers, MNC is being a December month we were not able to push the sales."
Balance Sheet & Fundraise
- INR125 crores preferential allotment completed in December: INR50 crores earmarked for debt repayment (including some long-term borrowings), INR75 crores for working capital and future expansion in FY25–26.
- Rationale was pre-emptive, not distress: Management cited multiple factors: need for capex on new products to start manufacturing in FY26, the two-quarter delay in the facility coming online, and the need to invest in new chemistry; raising funds was deemed better than stressing finances.
- Inventory overhang: Current inventory was much higher at INR100–160 crores because a couple of orders were put on hold; normalization is expected by March based on traction of new orders.
- Debt target: Bring debt-to-EBITDA down to close to 3.5x by FY26.
- 9M PAT compressed: PAT stood at just INR1 crore due to increased depreciation and finance costs from commencement of the new Pakhajan plant.
US Subsidiary & Geographic Expansion
- US subsidiary goes live next month: All formalities are completed; product will move to the warehouse, and actual revenue generation starts from March. The subsidiary will serve as a key distribution hub for American customers.
- No targets set yet: Management deflected questions on milestones or targets, saying it is too early to set targets for a new setup in a different geography.
- No further subsidiaries planned currently: Beyond Europe and the USA, no plans exist today, though management acknowledged additional locations could happen going forward depending on business growth.
Tariff Risk: Assumption, Not a Plan
- Base case is no India-specific tariff: Management is not anticipating a higher tariff on Indian product entering the USA; if any tariff comes, the assumption is it will be across the board, not targeted at products originating from India.
- No contingency outlined: When asked how strategy would change if higher tariffs materialize, management offered no specific contingency or strategy adjustment, stating only that India is not going to be punished badly on the tariff side.
Parag Jhaveri: "We are not anticipating that there will be a higher tariff on the Indian product getting into U.S.A. That's we are quite a bit uncertain. If there will be any tariff, it will be across the board, not only on product originate from India as of today, what we have a conversation with our friends."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Pakhajan utilization | Cross 50% capacity | March 2025 onwards |
| Q4 blended utilization | 35% to 40% | Q4 FY25 |
| Q4 volume growth | Aggregate growth of ~30% to 35% | By end of FY25 |
| FY25 total revenue | INR650 crores to INR670 crores | FY25 |
| Inventory normalization | Return to normal levels | By March 2025 |
| FY26 revenue | INR950 crores to INR1,000 crores | FY26 |
| FY26 EBITDA margin | 17% to 19% minimum | FY26 |
| FY26 exit utilization (Pakhajan) | 85% to 90% | Last quarter of FY26 |
| FY27 revenue | INR1,250 crores to INR1,300 crores, assuming both plants run full from day 1 | FY27 |
| FY27 EBITDA margin | 18% plus/minus one | FY27 |
| Debt-to-EBITDA | Close to 3.5x | By FY26 |
| New product capex | Triggered once Pakhajan utilization surpasses 70% | FY26 |
| Full Pakhajan asset monetization | Minimum 3 to 4 years from now | FY28–FY29 |
Key Metrics
| Metric | Q3 FY25 |
|---|---|
| Revenue from operations | ₹148 cr, +14.7% YoY, driven by 8% volume growth |
| Export share of revenue | 66% of total revenue |
| EBITDA | ₹27 cr, EBITDA margin of 18.4% |
| Gross margin | 38% to 39% is a sustainable level |
| Industrial chemicals revenue share | 79% of total revenue, vs 87% in Q3 FY24 |
| Consumer chemicals revenue share | 21% of total revenue |
| 9M FY25 revenue from operations | ₹486 cr, +15% YoY |
| 9M FY25 EBITDA | ₹83 cr, EBITDA margin of 16.8% |
| 9M FY25 PAT | ₹1 cr, impacted by higher depreciation and finance costs from new plant |
| FY25 revenue guidance | ₹650 cr to ₹670 cr |
| FY26 revenue guidance | ₹950 cr to ₹1,000 cr, EBITDA margin 17% to 19% |
| FY27 revenue guidance | ₹1,250 cr to ₹1,300 cr, EBITDA margin 18% plus/minus 1% |
| Pakhajan capacity utilization (December) | Close to 30% |
| Pakhajan utilization guidance (Q4 FY25 blended) | 35% to 40% |
| Pakhajan utilization guidance (exit Q4 FY26) | 85% to 90% |
| Fundraise via preferential allotment | ₹125 cr, ₹50 cr for debt repayment, ₹75 cr retained for working capital and future capex |
| Current cost of debt | 8.6% to 8.8% |
| Debt to EBITDA target by FY26 | Close to 3.5x |
| Q4 FY25 volume growth guidance | 30% to 35% aggregate growth by year-end |
| Inventory level | ₹100 cr to ₹160 cr, elevated due to orders on hold, expected to normalize by March |
| Peak utilization EBITDA capacity (both plants) | Roughly ₹220 cr to ₹240 cr (per an analyst's math) |